Prometheus Biosciences Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 150

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.8B

  • Investors
  • 1

Prometheus Biosciences General Information

Description

Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD.

Contact Information

Website
www.prometheusbiosciences.com
Formerly Known As
Precision IBD
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3050 Science Park Road
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Merck & Co.
Vertical(s)
Life Sciences
Corporate Office
  • 3050 Science Park Road
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prometheus Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 15-Apr-2023 $10.8B Completed Generating Revenue
7. PIPE 12-Dec-2022 Completed Generating Revenue
6. IPO 12-Mar-2021 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series D) 01-Jan-2021 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 09-Apr-2020 Completed Clinical Trials - Phase 2
3. Debt - General 01-Jan-2020 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 28-Nov-2018 $10.1M $13.8M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 09-Oct-2017 $3.69M $3.69M Completed Startup
To view Prometheus Biosciences’s complete valuation and funding history, request access »

Prometheus Biosciences Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D2
Series D1
Series C
Series B 26,666,667 $0.000100 $0.75 $0.75 1x $0.75 8.4%
Series A 14,979,200 $0.000100 $0.5 $0.5 1x $0.5 4.72%
To view Prometheus Biosciences’s complete cap table history, request access »

Prometheus Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, develop
Drug Discovery
San Diego, CA
150 As of 2026

Cambridge, MA
 

Indianapolis, IN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prometheus Biosciences Competitors (2)

One of Prometheus Biosciences’s 2 competitors is Vedanta Biosciences, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
Scioto Biosciences Venture Capital-Backed Indianapolis, IN
You’re viewing 2 of 2 competitors. Get the full list »

Prometheus Biosciences Patents

  • 255

    Total Documents Applications and Grants

  • Total Patents Families

  • 90

    Granted

  • 77

    Pending

  • Expiring in next 12 mo

Prometheus Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4780437-A1 Gpr35 modulators Pending 20-Sep-2023
WO-2025064325-A1 Gpr35 modulators Inactive 20-Sep-2023
AU-2024280413-A1 Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a Pending 26-May-2023
AU-2024280413-A9 Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a Pending 26-May-2023
EP-4719473-A1 Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a Pending 26-May-2023 A61P29/00
To view Prometheus Biosciences’s complete patent history, request access »

Prometheus Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prometheus Biosciences Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ascend Capital (Singapore) PE/Buyout Minority
Cedars-Sinai Corporation Minority
Cormorant Capital Real Estate Minority
Cowen Healthcare Investments Venture Capital Minority
Decheng Capital Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Prometheus Biosciences Acquisitions (1)

Prometheus Biosciences’s most recent deal was a Merger/Acquisition with Prometheus Laboratories for . The deal was made on 30-Jun-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Prometheus Laboratories 30-Jun-2019 Merger/Acquisition Biotechnology
To view Prometheus Biosciences’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Prometheus Biosciences ESG

Risk Overview

Risk Rating

Updated November, 08, 2026

19.23 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Prometheus Biosciences’s complete esg history, request access »

Prometheus Biosciences Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Prometheus Laboratories San Diego, CA 1995

Prometheus Biosciences FAQs

  • When was Prometheus Biosciences founded?

    Prometheus Biosciences was founded in 2016.

  • Where is Prometheus Biosciences headquartered?

    Prometheus Biosciences is headquartered in San Diego, CA.

  • What is the size of Prometheus Biosciences?

    Prometheus Biosciences has 150 total employees.

  • What industry is Prometheus Biosciences in?

    Prometheus Biosciences’s primary industry is Drug Discovery.

  • Is Prometheus Biosciences a private or public company?

    Prometheus Biosciences is a Private company.

  • What is the current valuation of Prometheus Biosciences?

    The current valuation of Prometheus Biosciences is .

  • What is Prometheus Biosciences’s current revenue?

    The current revenue for Prometheus Biosciences is .

  • How much funding has Prometheus Biosciences raised over time?

    Prometheus Biosciences has raised $907M.

  • Who are Prometheus Biosciences’s investors?

    Ascend Capital (Singapore), Cedars-Sinai, Cormorant Capital, Cowen Healthcare Investments, and Decheng Capital are 5 of 13 investors who have invested in Prometheus Biosciences.

  • Who are Prometheus Biosciences’s competitors?

    Vedanta Biosciences and Scioto Biosciences are competitors of Prometheus Biosciences.

  • When was Prometheus Biosciences acquired?

    Prometheus Biosciences was acquired on 15-Apr-2023.

  • Who acquired Prometheus Biosciences?

    Prometheus Biosciences was acquired by Merck & Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process